Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
07:30am, Tuesday, 26'th Aug 2025
CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
05:25pm, Friday, 15'th Aug 2025
Zevra Therapeutics (ZVRA) came out with a quarterly earnings of $1.21 per share versus the Zacks Consensus Estimate of $2.19. This compares to a loss of $0.48 per share a year ago.
Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript
08:43pm, Tuesday, 12'th Aug 2025
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Off
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
06:51pm, Tuesday, 12'th Aug 2025
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $1.43. This compares to a loss of $0.48 per share a year ago.
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
04:05pm, Tuesday, 12'th Aug 2025
Q2 2025 net revenue of $25.9 million , driven by product net revenue of $21.8 million
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
10:10am, Monday, 11'th Aug 2025
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'
09:51am, Friday, 08'th Aug 2025
Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Tuesday, 05'th Aug 2025
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
07:30am, Monday, 04'th Aug 2025
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
10:56am, Thursday, 31'st Jul 2025
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
01:01pm, Wednesday, 16'th Jul 2025
Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
10:05am, Wednesday, 16'th Jul 2025
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
